Swain SM, Tan AR, Gianni L, Kuemmel S, et al. Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer. Eur J Cancer 2022;178:70-81.
PMID: 36410207